

Original Article

Open Access

Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution

Byoung Hyuck Kim, MD^{1,2}, Kyubo Kim, MD, PhD³, Eui Kyu Chie, MD, PhD¹, Jeanny Kwon, MD, PhD^{1,4}, Jin-Young Jang, MD, PhD⁵, Sun Whe Kim, MD, PhD⁶, Do-Youn Oh, MD, PhD⁶, Yung-Jue Bang, MD, PhD⁶

¹Department of Radiation Oncology, Seoul National University College of Medicine, Seoul,

²Division of Biological Warfare Preparedness and Response, Armed Forces Medical Research Institute, Daejeon,

³Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul,

⁴Department of Radiation Oncology, Chungnam National University School of Medicine, Daejeon,

Departments of ⁵Surgery and ⁶Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Supplementary Data

Supplementary Table 1. Comparison of disease characteristics in patients with ECOG 0-1 and ECOG 2

Characteristic	ECOG 0-1 patients (n=111)	ECOG 2 Patients (n=21)	p-value
Residual disease			
R0	97 (87.4)	21 (100)	0.085
R1	14 (12.6)	0	
Lymph node metastasis			
No	73 (65.8)	16 (76.2)	0.350
Yes	38 (34.2)	5 (23.8)	
Histologic differentiation			
W/D, M/D	92 (82.9)	17 (81.0)	0.983
P/D	16 (14.4)	3 (14.3)	
Unknown	3 (2.7)	1 (4.8)	
Preoperative CA19-9 (U/mL)			
≥ 37	62 (55.9)	9 (42.9)	0.179
< 37	27 (24.3)	8 (38.1)	
Unknown	22 (19.8)	4 (19.0)	

Values are presented as number (%). ECOG, Eastern Cooperative Oncology Group; W/D, well-differentiated; M/D, moderately-differentiated; P/D, poorly-differentiated; CA19-9, carbohydrate antigen 19-9.